Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes

J Chang-Claude, H Becher, M Caligo, D Eccles, G Evans, N Haites, S Hodgson, P Moller, B H F Weber, D Stoppa-Lyonnet, EC Demonstration Project Familial

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

For genetic counselling of a woman on familial breast cancer, an accurate evaluation of the probability that she carries a germ-line mutation is needed to assist:in making decisions about genetic-testing.

We used data from eight collaborating centres comprising 618 families (346 breast cancer only, 239 breast or ovarian cancer) recruited as research families or counselled for familial breast cancer, representing a broad range of family structures. Screening was performed in affected women from 618 families for germ-line mutations in BRCA1 and in 176 families for BRCA2 mutations, using different methods including SSCP, CSGE, DGGE, FAMA and PTT analysis followed by direct sequencing. Germ-line BRCA1 mutations were detected in 132 families and BRCA2 mutations in 16 families. The probability of being a carrier of a dominant breast cancer gene was calculated for the screened individual under me established genetic model for breast cancer susceptibility, first, with parameters for age-specific penetrances for breast cancer only [7] and, second, with age-specific penetrances for ovarian cancer in addition [20]. Our results indicate that the estimated probability of carrying a dominant breast cancer gene gives a direct measure of the likelihood of detecting mutations in BRCA1 and BRCA2. For breast/ovarian cancer families, the genetic model according to Narod et al. [20] is preferable for calculating the proband's genetic risk, and gives detection rates that indicate a 50% sensitivity of the gene test. Due to the incomplete BRCA2 screening of the families, we cannot yet draw any conclusions with respect to the breast cancer only families.

Original languageEnglish
Pages (from-to)53-65
Number of pages13
JournalDisease Markers
Volume15
Publication statusPublished - 1999

Keywords

  • genetic counselling
  • genetic risk assessment
  • familial breast cancer
  • OVARIAN-CANCER
  • LINKAGE ANALYSIS
  • FAMILY HISTORY
  • BRCA2 MUTATION
  • COMMON BRCA1
  • POPULATION
  • FREQUENCY
  • CARRIERS
  • HETEROGENEITY
  • INDIVIDUALS

Cite this

Chang-Claude, J., Becher, H., Caligo, M., Eccles, D., Evans, G., Haites, N., ... EC Demonstration Project Familial (1999). Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. Disease Markers, 15, 53-65.

Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. / Chang-Claude, J ; Becher, H ; Caligo, M ; Eccles, D ; Evans, G ; Haites, N ; Hodgson, S ; Moller, P ; Weber, B H F ; Stoppa-Lyonnet, D ; EC Demonstration Project Familial.

In: Disease Markers, Vol. 15, 1999, p. 53-65.

Research output: Contribution to journalArticle

Chang-Claude, J, Becher, H, Caligo, M, Eccles, D, Evans, G, Haites, N, Hodgson, S, Moller, P, Weber, BHF, Stoppa-Lyonnet, D & EC Demonstration Project Familial 1999, 'Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes', Disease Markers, vol. 15, pp. 53-65.
Chang-Claude J, Becher H, Caligo M, Eccles D, Evans G, Haites N et al. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. Disease Markers. 1999;15:53-65.
Chang-Claude, J ; Becher, H ; Caligo, M ; Eccles, D ; Evans, G ; Haites, N ; Hodgson, S ; Moller, P ; Weber, B H F ; Stoppa-Lyonnet, D ; EC Demonstration Project Familial. / Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. In: Disease Markers. 1999 ; Vol. 15. pp. 53-65.
@article{79642ff62926452e9a8fc57fd2bc6a60,
title = "Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes",
abstract = "For genetic counselling of a woman on familial breast cancer, an accurate evaluation of the probability that she carries a germ-line mutation is needed to assist:in making decisions about genetic-testing.We used data from eight collaborating centres comprising 618 families (346 breast cancer only, 239 breast or ovarian cancer) recruited as research families or counselled for familial breast cancer, representing a broad range of family structures. Screening was performed in affected women from 618 families for germ-line mutations in BRCA1 and in 176 families for BRCA2 mutations, using different methods including SSCP, CSGE, DGGE, FAMA and PTT analysis followed by direct sequencing. Germ-line BRCA1 mutations were detected in 132 families and BRCA2 mutations in 16 families. The probability of being a carrier of a dominant breast cancer gene was calculated for the screened individual under me established genetic model for breast cancer susceptibility, first, with parameters for age-specific penetrances for breast cancer only [7] and, second, with age-specific penetrances for ovarian cancer in addition [20]. Our results indicate that the estimated probability of carrying a dominant breast cancer gene gives a direct measure of the likelihood of detecting mutations in BRCA1 and BRCA2. For breast/ovarian cancer families, the genetic model according to Narod et al. [20] is preferable for calculating the proband's genetic risk, and gives detection rates that indicate a 50{\%} sensitivity of the gene test. Due to the incomplete BRCA2 screening of the families, we cannot yet draw any conclusions with respect to the breast cancer only families.",
keywords = "genetic counselling, genetic risk assessment, familial breast cancer, OVARIAN-CANCER, LINKAGE ANALYSIS, FAMILY HISTORY, BRCA2 MUTATION, COMMON BRCA1, POPULATION, FREQUENCY, CARRIERS, HETEROGENEITY, INDIVIDUALS",
author = "J Chang-Claude and H Becher and M Caligo and D Eccles and G Evans and N Haites and S Hodgson and P Moller and Weber, {B H F} and D Stoppa-Lyonnet and {EC Demonstration Project Familial}",
year = "1999",
language = "English",
volume = "15",
pages = "53--65",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

TY - JOUR

T1 - Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes

AU - Chang-Claude, J

AU - Becher, H

AU - Caligo, M

AU - Eccles, D

AU - Evans, G

AU - Haites, N

AU - Hodgson, S

AU - Moller, P

AU - Weber, B H F

AU - Stoppa-Lyonnet, D

AU - EC Demonstration Project Familial

PY - 1999

Y1 - 1999

N2 - For genetic counselling of a woman on familial breast cancer, an accurate evaluation of the probability that she carries a germ-line mutation is needed to assist:in making decisions about genetic-testing.We used data from eight collaborating centres comprising 618 families (346 breast cancer only, 239 breast or ovarian cancer) recruited as research families or counselled for familial breast cancer, representing a broad range of family structures. Screening was performed in affected women from 618 families for germ-line mutations in BRCA1 and in 176 families for BRCA2 mutations, using different methods including SSCP, CSGE, DGGE, FAMA and PTT analysis followed by direct sequencing. Germ-line BRCA1 mutations were detected in 132 families and BRCA2 mutations in 16 families. The probability of being a carrier of a dominant breast cancer gene was calculated for the screened individual under me established genetic model for breast cancer susceptibility, first, with parameters for age-specific penetrances for breast cancer only [7] and, second, with age-specific penetrances for ovarian cancer in addition [20]. Our results indicate that the estimated probability of carrying a dominant breast cancer gene gives a direct measure of the likelihood of detecting mutations in BRCA1 and BRCA2. For breast/ovarian cancer families, the genetic model according to Narod et al. [20] is preferable for calculating the proband's genetic risk, and gives detection rates that indicate a 50% sensitivity of the gene test. Due to the incomplete BRCA2 screening of the families, we cannot yet draw any conclusions with respect to the breast cancer only families.

AB - For genetic counselling of a woman on familial breast cancer, an accurate evaluation of the probability that she carries a germ-line mutation is needed to assist:in making decisions about genetic-testing.We used data from eight collaborating centres comprising 618 families (346 breast cancer only, 239 breast or ovarian cancer) recruited as research families or counselled for familial breast cancer, representing a broad range of family structures. Screening was performed in affected women from 618 families for germ-line mutations in BRCA1 and in 176 families for BRCA2 mutations, using different methods including SSCP, CSGE, DGGE, FAMA and PTT analysis followed by direct sequencing. Germ-line BRCA1 mutations were detected in 132 families and BRCA2 mutations in 16 families. The probability of being a carrier of a dominant breast cancer gene was calculated for the screened individual under me established genetic model for breast cancer susceptibility, first, with parameters for age-specific penetrances for breast cancer only [7] and, second, with age-specific penetrances for ovarian cancer in addition [20]. Our results indicate that the estimated probability of carrying a dominant breast cancer gene gives a direct measure of the likelihood of detecting mutations in BRCA1 and BRCA2. For breast/ovarian cancer families, the genetic model according to Narod et al. [20] is preferable for calculating the proband's genetic risk, and gives detection rates that indicate a 50% sensitivity of the gene test. Due to the incomplete BRCA2 screening of the families, we cannot yet draw any conclusions with respect to the breast cancer only families.

KW - genetic counselling

KW - genetic risk assessment

KW - familial breast cancer

KW - OVARIAN-CANCER

KW - LINKAGE ANALYSIS

KW - FAMILY HISTORY

KW - BRCA2 MUTATION

KW - COMMON BRCA1

KW - POPULATION

KW - FREQUENCY

KW - CARRIERS

KW - HETEROGENEITY

KW - INDIVIDUALS

M3 - Article

VL - 15

SP - 53

EP - 65

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

ER -